In a healthcare environment that is trying to achieve better clinical outcomes and patient satisfaction, shared decision-making is a well-established concept that is gaining more interest. Multiple sclerosis is a preference-sensitive condition and provides the opportunity to implement decision aids at various decision points in the disease process. Literature about patient education and outcomes of shared decision aids in multiple sclerosis has been growing over the last decade. In this topical review, we present an overview of the current literature on shared decision-making in multiple sclerosis. While limitations to the generalizability and applicability of decision aids exist, there is evidence that decision aids and shared decision-making can be valuable tools in the clinical care of multiple sclerosis patients.
Introduction
Shared decision-making is an effective, yet underutilized, tool in patient-centered care. 1, 2 Medicine is moving away from paternalism and toward patient autonomy both legally and ethically. [3] [4] [5] [6] In paternalism, the physician decides what care is in the patient's best interest and expects the patient to be compliant with the treatment recommended. 4 In a shared decision-making model, in contrast to paternalism, the physician elicits the patient's values and preferences about their care, has an evidence-based discussion of treatment options, and then the patient and physician arrive at a treatment decision together. 1, 7, 8 Shared decision-making has been shown to be particularly useful in preference-sensitive conditions, 7 in which there exist a number of available treatment options of similar efficacy, with differences in risks and benefits. Relapsing-remitting multiple sclerosis (RRMS) is one such disease. This is distinct from conditions such as bacterial meningitis, where there are clearly established best practices, and time may be limited; therefore, the patient is generally informed of their treatment, rather than participating in the treatment discussion. In this topical review, the concept of shared decision-making is discussed, and the current literature on shared decision-making in multiple sclerosis (MS) is summarized.
Shared decision-making
In shared decision-making, the provider informs the patient that there is a decision to be made and asks about the patient's values and preferences to determine their treatment options. 4 In one recently published approach to conducting shared decision-making in the clinical setting, the physician first elicits the patient's values and goals about their care. 7 These patient goals are solicited with careful exploration of life experiences, psychosocial circumstances, and health status. 4 The physician then has a discussion of all evidence-based treatment options that are in line with the patient's goals, including the option not to treat, when appropriate. Subsequently, the physician partners with the patient to make a decision that is consistent with the patient's personal situation (see Figure 1 ). 7 For example, in a discussion of treatment options for RRMS, the physician can discuss how starting a disease-modifying medication will help the patient achieve their goals (i.e. fewer relapses in order to be able to parent young children) and avoid an undesired risk (i.e. the possibility of making depression worse with beta-interferons). The patient will then decide, with the help of the physician, which of the treatment options is most consistent with their preferences. Shared decision-making has been described as the pinnacle of patient-centered care. 1 Physicians often assume that they know or can intuit their patients' needs and wants. 8 In fact, when studied, physicians are not skilled in assessing the amount and quality of the information that patients desire to make high-quality, complex medical decisions. 4, 8, 9 In MS, research shows that patients have unmet information needs and desire more education about MS symptoms, prognosis, and management than they currently receive from their neurologists. [10] [11] [12] Of course, not all patients will desire to make a shared decision with their physicians. However, when patient preference has been studied in MS, 91% of patients preferred to make an autonomous or shared decision, as opposed to only 9% who preferred to have the physician make a decision for them. 13 Below, we will discuss the tools that have been developed to try to meet the needs of MS patients at various decision points in the progression of MS, including educational programs, information aids, and decision aids (DAs), and make a case for the use of shared decision-making as an ethical imperative.
Educational programs and information aids in MS
Many educational programs have been developed for MS to try to address MS patients' unmet information needs. 14 Of particular interest is the Relapse Management Program, which is an educational program focused on steroid use in MS exacerbations. 13, 15, 16 This program is notable as an example of how shared decision-making can change treatment decisions. In the study, the intervention group participated in a 4-hour course and received a 40-page educational booklet, which provided information on relapses, the evidence for and side effects of steroid therapy, and information about intravenous versus oral steroid therapy. 13, 15, 16 The control group received standard-of-care: a 2-page booklet on treatment options. The participants were prescribed high-dose oral steroids to take when they experienced relapses. In 78% of all relapses in the intervention group, patients opted not to use intravenous steroid therapy and instead chose to use oral or no steroids; this was compared to 56% in the control group. Quality of life, disability status, and adverse effects of steroids were similar between the groups. In addition, patients had better risk knowledge and autonomy of treatment in the intervention group. 13, 15, 16 MS educational programs regarding whether to initiate treatment early in the disease course have been shown to increase disease knowledge and satisfaction with care. 17, 18 Patients who received more information did not show an increase in anxiety or depression, which can be a concern when sharing information about MS. 15, [17] [18] [19] Importantly, patients with increased This framework for patient engagement and shared decision-making (SDM) in clinical visits shows patients at the top providing overall guidance, supported by carepartners and caregivers when relevant. Patients' values (blue) inform their goals (green) and both inform evidence-based discussion of healthcare options (e.g. tests, treatments) and decisions regarding the best options to achieve their goals. The three steps for patient engagement and SDM are outlined (boxes), with each step requiring participation by both physicians and patients. In neurology, this process most commonly occurs in the setting of clinical uncertainty, but it is relevant in situations with clinical certainty as well. Reprinted with permission. 7 knowledge of clinical uncertainties regarding MS treatments did not opt out of taking effective therapies. 18 A recent Cochrane review was performed on MS information and decision-support programs. 14 MS patients are able to handle complex information regarding clinical uncertainties without adverse effects, 13, 15, 16, 20 and therefore, MS patients are an optimal patient population to use shared decision-making.
Shared decision-making tools and outcomes
DAs are patient education instruments that are specifically designed to facilitate shared decision-making. DAs present the decision to be made (i.e. which medication to take in relapsing-remitting MS), as well as the evidence, benefits, and risks of the various options, and elicit the patient's values and preferences to make an informed decision. They are meant to supplement clinical encounters, not to replace the time the patient spends with their physician. DAs can be presented in a variety of formats, including text, video-based, and web-based. The International Patient Decision Aids Standards (IPDAS) forum has created criteria for high-quality DAs (see Table 1 for a summary of criteria). 21 A recent Cochrane review found that DAs increase patient knowledge and help patients develop accurate risk perceptions when probabilities are presented. 22 When values are clarified in an explicit fashion, patients select an option that is congruent with their values. 22 Patients who use DAs, as compared to usual care, experience reduced decisional conflict, as they feel more informed and their personal values are clarified. 22 Patient satisfaction, a metric increasingly used in healthcare, has improved in some studies with use of a DA, although these studies were not completed in MS. 22 Studies on DAs in MS have not studied the cost-effectiveness of implementing a DA. [17] [18] [19] [20] There are many decision points during the disease course of MS that are well suited for shared decisionmaking, including whether to take steroids for an acute relapse; which immunotherapy drug to take, if any; whether to initiate disease-modifying drugs (DMDs) early in the disease course; and whether to have a child after being diagnosed with MS. These are all preference-sensitive issues, where the patient's values and preferences can and should contribute to the ultimate decision. To facilitate these discussions between patients and physicians, groups in Germany, Italy, the United Kingdom, Australia, and the United States are developing shared decision-making tools for MS. [16] [17] [18] 20, 23, 24 Kasper et al. 23 and Heesen et al. 16 developed DAs of different lengths for the use of immunotherapy in MS.
In pilot studies, patients preferred the longest version of the DA, which was 80 pages in length, when given the options of short, medium, and long versions of the tool. The DA divided the decision into "whether immunotherapy" and "which immunotherapy," including only information about interferons. 16, 23 The intervention group who received the DA evaluated immunotherapy more critically than the control group and felt better informed and supported in their interactions with their providers than the control group. 16, 23 There was no difference between the two groups for starting, stopping, or changing immunotherapy. 16, 23 There were no adverse effects for using a DA, including no increased anxiety or depression in the intervention group. 16, 23 DAs have not been shown to affect adherence, but since 91% of MS patients in this study were found to prefer an autonomous or shared decision, utilizing DAs is consistent with allowing patients to participate in their care in the way they desire. 23 Prunty et al. 20 created a DA for women with MS who are considering pregnancy. This is a difficult decision for patients with MS, as the disease commonly starts during childbearing years, and there is uncertainty as to how the disease will progress. Before this study, women with MS reported no information to help them make a decision for or against pregnancy. 25 The women in the intervention group who received the DA in addition to standard of care were found to be more knowledgeable about pregnancy in MS, had higher self-efficacy, higher certainty about their decision, and therefore decreased decisional conflict. 20 The DA did not change patients' minds about having a child, and there were no adverse effects. 20 The future of DAs in MS likely will rely on tools made available through the Internet. MS Trust from the United Kingdom has created a website that is an evidence-based resource for MS disease-modifying therapies. 24 Through the site, patients can compare medications, side effects, and routes of administration. 24 The authors of this paper have also made a DA of MS injectable medications available online, using the Ottawa Hospital Research Institute Patient Decision Aids Development Toolkit. 26, 27 As more MS medications come to the market, the true challenge in creating a decision tool that is helpful to patients is keeping it within a reasonable length and readability. The rapidly changing, commercially influenced environment of MS drug development can make it difficult to reach a conclusion regarding relative efficacy or risk profile comparisons.
Benefits of shared decision-making
Ethical imperatives of patient autonomy, patient education, and patient-centered care are all accomplished in a shared decision-making model. 8, 28 Patients report improved satisfaction and lower decisional conflict when participating in shared decision-making. 28 Internationally, multiple organizations are advocating for shared decision-making. 29 Participants from 18 countries created the Salzburg Statement on Shared Decision-Making, which states that shared decisionmaking is an ethical imperative and recommend its widespread use in clinical practice. 29, 30 In the United States in 2001, the Institute of Medicine published "Crossing the Quality Chasm," which identified patient-centered care using a shared decision-making model as one of the six aims to improve high-quality healthcare delivery. 31 The 21st Century Initiative, led by Steering Group of International Experts in MS treatment and management, identified the topic of patient engagement in MS to require the most urgent action. 5 DAs are a very appealing tool to pursue this goal.
Limitations of shared decision-making
While DAs and shared decision-making have been shown to improve patient education and patientcentered care, 8,28 many physicians have legitimate concerns about them. In studies, shared decisionmaking has not demonstrably increased patient adherence to medical therapy or improved outcomes. 28 Although DAs consistently demonstrate improvement in patient knowledge and reduced decisional conflict, on further examination using videotaped analysis and shared decision-making scales, shared decision-making has not always taken place. 28 Therefore, the question is raised as to whether shared decision-making itself is responsible for positive outcomes seen when using DAs.
In some current reimbursement models in healthcare, physicians may worry that shared decision-making will add non-reimbursable time to their already busy practices. The Cochrane review of DAs found that DAs made visits between 8 minutes shorter to 23 minutes longer (median 2.55 minutes longer). 22 With the increasing number of disease-modifying therapies available for MS, these discussions are unlikely to decrease in length. Additionally, DAs have not been studied in lower literacy populations or among other cultures, who do not speak the dominant language and may be more or less deferential to a physician. 4, 22 Another limitation of DAs that applies to the United States is that insurance companies often restrict firstline MS drugs, thereby making shared decision-making of different MS medications difficult to impossible. 32 Information or physician bias is another concern. There have not been enough studies that specifically examine cost to make a statement on cost-effectiveness of shared decision-making in MS. 14, 22 
Conclusion
It has been proposed that physicians and other healthcare providers have an ethical imperative to use shared decision-making in preference-sensitive conditions. MS is an ideal disease process for shared decisionmaking due to a multitude of potential interventions that are evidence-based and similarly effective, and the MS patient has been shown to be able to handle complex clinical information. 13, 15, 16, 20 Research teams around the world have investigated many key decision points in disease management, and decision tools are available for a wide variety of interventions. 17, 18, 23, 24 There is controversy about the successful application of shared decision-making tools, such as time constraints or utility in lower literacy populations and different cultures, which requires further investigation and process refinement. 22, 28 The benefits of improved patient engagement and knowledge have been demonstrated and replicated in several studies in MS patients. 17, 18, 20, 23 There are significant barriers to researching the efficacy of shared decision-making in MS. Meaningful implementation can be difficult to observe and outcome measures such as long-term treatment adherence, clinical patient outcomes, or cost of care can be hard to capture.
Despite these remaining knowledge gaps, the authors of this paper propose that the potential benefits of shared decision-making using DAs outweigh the risks inherent to adopting a new practice. Physicians who treat MS patients routinely provide patient education with the aim of improving patient knowledge. Implementing a DA would help to ensure that the patient's values and preferences are being considered consistently and that patients are more engaged in their care. In most cases, shared decision-making has not been shown to change medical management; however, it is not designed to do so. Medical decision-making is inherently complex, and shared decision-making is useful in educating patients, so they can make an informed decision with their physicians that is aligned with their personal values and preferences. The goal is not for the patient to pick one treatment choice instead of another; rather, the goal is to help patients be more comfortable with their decisions and allow them to actively participate in their care. As physicians, we have an ethical responsibility to educate patients, present them with options, and allow them to participate in their care in the way they desire.
